PMID- 27471615
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160729
LR  - 20210112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 5
IP  - 6
DP  - 2016 Jun
TI  - A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with 
      PD-L1 blockade elicits therapeutic antitumor immunity in mice.
PG  - e1147641
LID - 10.1080/2162402X.2016.1147641 [doi]
LID - e1147641
AB  - Human papilliomavirus (HPV) oncogene E7, essential for the transformation and 
      maintenance of the malignancy of cervical cancer cells, represents an ideal 
      tumor-specific antigen for vaccine development. However, due to the poor 
      immunogenicity of E7 protein, an effective therapeutic E7 vaccine is still 
      lacking. Dendritic cells (DCs) are probably the most potent antigen presenting 
      cells for the induction of cytotoxic T lymphocyte (CTL) response, which is 
      crucial for tumor control. In this study, we tested whether targeting the E7 
      antigen to DCs in vivo would elicit therapeutic antitumor CTL response. We 
      generated the DEC205-specific single-chain variable fragment (scFv) and E7 long 
      peptide fusion protein [scFv(DEC205)-E7] based on the novel method of protein 
      assembly we recently developed. This fusion protein vaccine demonstrated highly 
      efficient DC-targeting in vivo and elicited much stronger protective CTL response 
      than non-DC-targeting control vaccine in naive mice. Furthermore, the 
      scFv(DEC205)-E7 vaccine showed significant therapeutic antitumor response in TC-1 
      tumor bearing mice. Importantly, PD-L1 blockade further improved the therapeutic 
      effect of the scFv(DEC205)-E7 vaccine. Thus, the current study suggests an 
      efficient strategy for cervical cancer immunotherapy by combining the 
      DC(DEC205)-targeting E7 vaccine and PD-L1 blockade.
FAU - Liu, Zhida
AU  - Liu Z
AD  - Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese 
      Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, 
      Beijing, China; Department of Pathology, University of Texas, Southwestern 
      Medical Center, Dallas, TX, USA.
FAU - Zhou, Hang
AU  - Zhou H
AD  - Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese 
      Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, 
      Beijing, China.
FAU - Wang, Wenjun
AU  - Wang W
AD  - Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese 
      Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, 
      Beijing, China.
FAU - Fu, Yang-Xin
AU  - Fu YX
AD  - Department of Pathology, University of Texas, Southwestern Medical Center , 
      Dallas, TX, USA.
FAU - Zhu, Mingzhao
AU  - Zhu M
AD  - Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese 
      Academy of Sciences , Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160310
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC4938372
OTO - NOTNLM
OT  - Cervical cancer
OT  - DEC205
OT  - HPV E7
OT  - PD-1
OT  - PD-L1
OT  - dendritic cell
OT  - therapeutic vaccine
EDAT- 2016/07/30 06:00
MHDA- 2016/07/30 06:01
PMCR- 2017/03/10
CRDT- 2016/07/30 06:00
PHST- 2015/09/29 00:00 [received]
PHST- 2016/01/18 00:00 [revised]
PHST- 2016/01/24 00:00 [accepted]
PHST- 2016/07/30 06:00 [entrez]
PHST- 2016/07/30 06:00 [pubmed]
PHST- 2016/07/30 06:01 [medline]
PHST- 2017/03/10 00:00 [pmc-release]
AID - 1147641 [pii]
AID - 10.1080/2162402X.2016.1147641 [doi]
PST - epublish
SO  - Oncoimmunology. 2016 Mar 10;5(6):e1147641. doi: 10.1080/2162402X.2016.1147641. 
      eCollection 2016 Jun.